Loading...
•
Jun 30, 2022
Terns Q2 2022 Earnings Report
Terns Pharmaceuticals reported financial results for the second quarter ended June 30, 2022.
Key Takeaways
Terns Pharmaceuticals reported a net loss of $13.9 million for the second quarter ended June 30, 2022. As of June 30, 2022, cash, cash equivalents and marketable securities were $139.8 million.
TERN-701 (allosteric BCR-ABL inhibitor) advances into Phase 1 trial for CML in China
IND-enabling activities for TERN-601 (GLP-1R agonist) remain on track; Phase 1 obesity trial initiation expected in 2023
Initiated dosing of TERN-501 (THR-β agonist) Phase 2a DUET combo clinical trial for NASH; top-line data expected in second half of 2023
Cash and equivalents of $140 million provides runway into 2025, supporting three expected clinical trial readouts across three product candidates and three indications
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...